Related Experiment Video
Updated: Mar 29, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.4K
Association Between COX-2 Polymorphisms and Lung Cancer Risk.
Weiwei Wang1, Xinyun Fan2, Yong Zhang1
1Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Provincial Tumor Hospital, Kunming, Yunnan, China (mainland).
Summary
This meta-analysis investigated cyclooxygenase-2 (COX-2) gene polymorphisms and lung cancer risk. The COX-2 rs20417 variant was associated with reduced lung cancer risk, while rs2066826 showed an increased risk.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- Lung cancer risk is influenced by various factors, but previous study results are inconsistent.
- A comprehensive conclusion requires summarizing existing data through meta-analysis.
Purpose of the Study:
- To conduct a meta-analysis on the relationship between cyclooxygenase-2 (COX-2) gene polymorphisms and lung cancer risk.
- To clarify the inconsistent findings regarding risk factors for lung cancer.
Main Methods:
- Utilized STATA 12.0 software for statistical analysis of COX-2 polymorphisms and lung cancer risk.
- Assessed inter-study heterogeneity using the Q statistic and publication bias with Begg's funnel plot and Egger's test.
- Tested Hardy-Weinberg equilibrium in all study controls.
Main Results:
- The COX-2 rs20417 polymorphism showed a significant association with reduced lung cancer risk under homozygous and recessive models.
- This reduced risk was also observed in white and population-based subgroups.
- The COX-2 rs2066826 polymorphism was strongly correlated with an increased risk of lung cancer across five genetic models.
Conclusions:
- The COX-2 rs20417 polymorphism may be associated with a decreased risk of lung cancer.
- Conversely, the COX-2 rs2066826 polymorphism may be linked to an elevated risk of lung cancer.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:05Single Nucleotide Polymorphisms-SNPs
19.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
118
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
118
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
158
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158
01:33Cancer-Critical Genes I: Proto-oncogenes
11.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.9K